Kenny Walter

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

In Philadelphia, 28% of the patient population was unscreened, with the factors associated with lower risks of being unscreened generally associated with a higher HCV positivity rate.

The approval, awarded to Alnylam Pharmaceuticals, is based on the results of the ILLUMINATE-C phase 3 trial.

The results also show a bigger increase among adults between 2012-2017, which could be due to increased sensitivity of diagnosis.

Recent qualitative studies found social isolation in patients with IBD is 1 of the main obstacles to leading a normal life.

A duration-response analysis of 1-mg dosage produced a 5% decrease in suicidal events per month of additional treatment.

The new recommendations call for posterior partial fundoplication over total posterior or anterior 90° fundoplication in adult patients with GERD and anterior >90° fundoplication as an alternative.

Overall, 30.60% of pediatric patients who presented to the emergency department with mild head trauma were diagnosed with ADHD, compared to 8.96% of the control group.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

Vedolizumab was linked to an increased risk of treatment failure compared to TNF antagonists.

ADHD and ODD dimensions were associated differently with different types of impulsivity, with unique patterns of network connectivity.

The FDA approved risankizumab for patients with Crohn's disease in June.

The investigators identified Osteoprotegerin in the serum of dupilumab treated patients, which could act as a predictor for clinical outcomes of dupilumab treatment.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.

The investigators found minor differences in the microbial community structure between the control group and the chronic HCV group.

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

A significantly lower rate of C difficile resolution was found in the placebo group compared to the FMT group.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

DBV Technologies is expected to provide additional updates after a consultation with the FDA.

The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.

Concurrent metabolic syndrome was independently linked to a worse overall and recurrence-free survival rates.

The genus most consistently associated with Crohn’s disease was Fusobacterium, but disease-associated genera were mostly inconsistent between studies.

In the group positive for HCV by RNA testing in the emergency department, the linkage to care was just 44.1%, compared to 67.6% for patients in outpatient clinics and 50.9% for patients in inpatient units.

High CPAP adherence also resulted in a significant protective effect on the 30-day readmission for beneficiaries with heart failure.

Patients with IBD were approximately 3.5 times more likely to have moderate or severe periodontitis.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

The increase in EoE incidence was most pronounced in men and for patients aged 40 years and older.